8 terminated. 8 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 4 | Terminated 4 |
| Phase 3 | 1 | Terminated 1 |
Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult | Phase 1 / Phase 2 | Terminated | BlueSphere Bio, Inc | 2 | 2025-02-04 | 2026-09-10 |
| A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure Vibecotamab, Dexamethasone, Acetaminophen - AML, MDS | Phase 2 | Terminated | M.D. Anderson Cancer Center | 51 | 2022-05-06 | 2026-05-22 |
| A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations E6201 - AML, MDS | Phase 1 / Phase 2 | Terminated | Spirita Oncology, LLC | 27 | 2015-04-10 | 2019-03-20 |
| A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes Lenalidomide and azacitidine combination - MDS | Phase 2 | Terminated | Rush University Medical Center | 2 | 2011-01-01 | 2020-11-19 |
| A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients Lenalidomide - Myelodysplastic Syndrome, MDS | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 8 | 2008-07-01 | 2025-05-04 |
| Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft Naive T-cell Depleted Stem Cell Transplant, Stem Cell Transplant No Manipulation, Isolex device from Baxter - ALL, ANLL | Phase 1 / Phase 2 | Terminated | Duke University | 15 | 2007-07-01 | 2013-11-25 |
| Velcade in Myelodysplastic Syndrome - Pilot Study Velcade - MDS | Phase 2 | Terminated | Gruppo Italiano Malattie EMatologiche dell'Adulto | 28 | 2006-08-01 | 2015-04-23 |
| Stem Cell Transplantation for Hematological Malignancies Stem Cell Transplant, Busulfan, Cyclophosphamide - Leukemia, Lymphocytic, Acute, AML | Phase 2 / Phase 3 | Terminated | Masonic Cancer Center, University of Minnesota | 11 | 2000-06-07 | 2017-12-05 |
Leukemia, Myeloid, Acute (2) · Hematologic Neoplasms (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Leukemia (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Leukemia, Myeloid (2) · Bone Marrow Diseases (1) · Disease Attributes (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms by Site (1) · Pathologic Processes (1)
Lenalidomide (2) · 14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione (1) · Acetaminophen (1) · Antilymphocyte Serum (1) · Azacitidine (1) · Bone Marrow Transplantation (1) · Bortezomib (1) · Busulfan (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Dexamethasone (1) · Diphenhydramine (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Melphalan (1)
BlueSphere Bio, Inc (1) · Duke University (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · M.D. Anderson Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Rush University Medical Center (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Spirita Oncology, LLC (1)
United States (6) · Italy (1)
Emmanuel Besa, MD (1) · Gautam Borthakur, MD (1) · Jamile M Shammo, MD (1) · Margaret MacMillan, MD (1) · Mitchell Horwitz, MD (1) · Nicholas Short, MD (1)